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Abstract
Rationale: More information on risk factors for death from tuberculosis in the United States 
could help reduce the tuberculosis mortality rate, which has remained steady for more than a 
decade.
Objective: To identify risk factors for tuberculosis-related death in adults.
Methods: We performed a retrospective study of 1,304 adults with tuberculosis who died before 
treatment completion and 1,039 frequency-matched control subjects who completed tuberculosis 
treatment in 2005 to 2006 in 13 states reporting 65% of U.S. tuberculosis cases. We used in-depth 
record abstractions and a standard algorithm to classify deaths in persons with tuberculosis as 
tuberculosis-related or not. We then compared these classifications to causes of death as coded in 
death certificates. We used multivariable logistic regression to calculate adjusted odds ratios for 
predictors of tuberculosis-related death among adults compared with those who completed 
tuberculosis treatment.
Results: Of 1,304 adult deaths, 942 (72%) were tuberculosis related, 272 (21%) were not, and 90 
(7%) could not be classified. Of 847 tuberculosis-related deaths with death certificates available, 
378 (45%) did not list tuberculosis as a cause of death. Adjusting for known risks, we identified 
new risks for tuberculosis-related death during treatment: absence of pyrazinamide in the initial 
regimen (adjusted odds ratio, 3.4; 95% confidence interval, 1.9–6.0); immunosuppressive 
medications (adjusted odds ratio, 2.5; 95% confidence interval, 1.1–5.6); incomplete tuberculosis 
diagnostic evaluation (adjusted odds ratio, 2.2; 95% confidence interval, 1.5–3.3), and an 
alternative nontuberculosis diagnosis before tuberculosis diagnosis (adjusted odds ratio, 1.6; 95% 
confidence interval, 1.2–2.2).
Conclusions: Most persons who died with tuberculosis had a tuberculosis-related death. 
Intensive record review revealed tuberculosis as a cause of death more often than did death 
certificate diagnoses. New tools, such as a tuberculosis mortality risk score based on our study 
findings, may identify patients with tuberculosis for in-hospital interventions to prevent death.
Keywords
cause of death; risk factors; death certificates
Americans still die of tuberculosis (TB), a preventable disease (1). On the basis of death 
certificate data, the TB mortality rate in the United States was 0.2/100,000 population, or 
555 deaths, in 2013 and has not changed since 2003 (2). Despite the importance of TB 
mortality, limited information has been published about patients who die of TB and the 
frequency of potentially preventable deaths.
Many studies have documented the need for a systematic approach to measure TB-related 
deaths and determine the role that TB played in death. However, such studies often use death 
certificates as their main data source. Death certificates can misclassify the cause of death 
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and underestimate the number who died with TB (3–7). One study of death certificates 
found TB listed as an underlying or contributing cause of death in only 34% of persons who 
died with TB (4). In a survey of resident physicians, only 33% who completed death 
certificates believed the death certificates were accurate; 20% who reported entering an 
incorrect cause of death stated they had done so because they were not familiar with the 
patient (5). Although some studies have examined TB-related mortality beyond death 
certificates, many were limited by narrowly defined populations or small size (6, 8–12).
Identifying risk factors for TB mortality could assist in the design of preventive 
interventions. Our primary objectives were to quantify and assess risk factors for TB-related 
deaths in the United States.
Methods
There were 1,304 adults with a verified diagnosis of TB (as reported to the Centers for 
Disease Control and Prevention [CDC]) who died in the 15 study catchment areas in 2005 
and 2006 (see Table E1 in the online supplement). All patients were included who were 
reported as dead at diagnosis or if the reason for treatment cessation was “died” on the 
Report of Verified Case of Tuberculosis form.
For all of the aforementioned study subjects, trained data abstractors from each study site 
reviewed inpatient and outpatient medical and laboratory records and immediate, 
underlying, and contributing causes of death from the death certificates and entered into the 
abstraction form for the patient.
All persons evaluating the TB relatedness of death took a 2-hour training where the TB-
relatedness algorithm was reviewed and sample cases were discussed to ensure consistency 
of review. In addition, all persons performing TB-relatedness determinations referred to a 
TB-relatedness flowchart and procedural manual to ensure consistency of classification. Two 
study team members, at least one of whom was a clinician with TB expertise, reviewed each 
data abstraction form and independently classified each death as possibly or definitely TB 
related, unlikely or definitely not related, or unclassifiable, using an a priori algorithm 
(Figure E1). Disagreements were resolved by a third independent reviewer. For the final 
analysis, definitely and possibly TB-related deaths were classified as TB-related deaths, and 
unlikely or definitely not TB-related deaths were classified as TB- unrelated deaths. This 
classification is used for all analyses.
A Kaplan-Meier curve was created to compare the time to death for patients who died with a 
TB-related death and patients who died with a TB-unrelated death.
To study risk factors for TB-related death during therapy, persons who died before diagnosis 
or treatment initiation were excluded from the cases. Only adults were included because of 
the small number (n = 14) of pediatric (<18 yr) deaths. Control subjects were selected from 
the group of patients with verified TB reported in the catchment areas from 2005 to 2006, 
who had completed TB treatment (which may last up to 2 years after treatment initiation; 
approximately 18,000 patients). Control patients were frequency matched 1:1 to cases by 
catchment area and age category. As with cases, control medical records were abstracted in 
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each study site by reviewing inpatient and outpatient medical and laboratory records. All 
available data for each control were entered into the data abstraction form.
All subjects were designated as having severe or extensive TB disease if they had acid-fast 
bacilli on smear microscopy (smear-positive disease), respiratory failure, bilateral 
pulmonary disease, extensive pulmonary destruction, pulmonary and extrapulmonary 
disease, or TB meningitis.
We analyzed categorical variables with the chi-square or Fisher exact test and continuous 
variables with the Wilcoxon rank sum test. We used the kappa coefficient to compare 
agreement on TB-related deaths between study algorithm and death certificate.
We assessed risk factors known to contribute to TB-related death from previous studies as 
well as novel risk factors we hypothesized to be associated with TB-related death. 
Covariates associated with TB-related death in bivariable models (P < 0.2) were included in 
multivariable logistic regression models. Respiratory failure was excluded from all models 
because it is on the causal pathway for TB-related death (13). If covariates were correlated 
(phi value ≥ 0.3), only the variable associated with the highest proportion of patients was 
included in the model. We excluded covariates that represented limited exposure 
opportunities for patients who died within the first month of treatment (health department 
monitoring, adverse reactions to TB therapy, treatment interruptions). Age, sex, meningeal 
TB status, and human immunodeficiency virus (HIV) status were included a priori in all 
models.
Covariates were added in descending order of bivariable odds ratios and were retained if 
their addition yielded a Wald chi-square P value ≤ 0.05 and 1) changed the adjusted odds 
ratio associated with meningeal TB or HIV by at least 10% (14), or 2) improved the model 
fit as indicated by the likelihood ratio test. Interactions that were tested included HIV by 
meningeal TB, HIV by cognitive impairment, and HIV by sputum smear status, and absence 
of pyrazinamide in the initial treatment regimen by “liver condition” (defined as patient with 
cirrhosis or viral hepatitis or patient reported excess alcohol usage). Data were analyzed 
using SAS 9.3.
Institutional Review Boards at CDC and each study site approved the study. This study was 
funded by the Division of Tuberculosis Elimination, National Center for HIV, STD, and TB 
Prevention, Centers for Disease Control and Prevention, through a task order announced and 
managed by the Tuberculosis Epidemiologic Studies Consortium.
Results
The 1,318 deaths included 14 children and accounted for 52% of all deaths among 
individuals with TB in the United States during 2005 to 2006. Of the 1,304 adult deaths, 942 
(72%) were TB related, 272 (21%) were not, and 90 (7%) were unclassifiable (Figure 1). 
Review of 331 records indicated 87% agreement between the first and second reviewers on 
TB relatedness of death. TB-related death occurred during treatment for 705 decedents 
(75%) and before treatment began for 237 (25%), of whom 202 (85%) died before diagnosis. 
Of the 705 who died during treatment, 329 (47%) died within 30 days of diagnosis and 371 
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(53%) died later; 5 (0.7%) had missing dates (Figure 1). Figure 2 shows that those who had 
a TB-related death died sooner after their TB diagnosis than those who died of other causes.
Almost all (98%) of the 942 adult patients with TB-related deaths had culture-confirmed 
TB: 228 of 237 who died before TB treatment, and 692 of 705 who died during treatment. 
Of the 755 Mycobacterium tuberculosis isolates with drug susceptibility results, 58 (8%) 
were monoresistant (41 to isoniazid, 16 to pyrazinamide, and 1 to rifampin), 4 (0.5%) were 
resistant to more than one drug, and 14 (2%) displayed multidrug-resistant TB, defined as 
resistance to at least isoniazid and rifampin.
Among the 942 patients with TB-related deaths, 789 (84%) had at least one of the following: 
smear-positive disease (54%), bilateral pulmonary lesions (44%), extensive pulmonary 
destruction visible on chest image (31%), pulmonary and extrapulmonary disease (23%), 
meningeal TB (10%), or miliary TB (7%). Concurrent medical conditions included chronic 
obstructive pulmonary disease (COPD) (25%), diabetes mellitus (25%), coronary artery 
disease (20%), viral hepatitis (12%), cancer (11%), and cirrhosis (10%) (Table 1).
Of the 237 cases with TB-related deaths who died before starting treatment, 82% had 
pulmonary/pleural involvement; 10% had cavitary lesions on chest radiographs. Notably, 
40% had an initial diagnosis other than TB, 56% had no TB nucleic acid amplification test 
performed, and 51% did not have a full TB diagnostic evaluation. Compared with those who 
died during treatment, cases who died before starting treatment were more likely to have 
extrapulmonary TB, unknown HIV status, a diagnosis or history of cancer, or no reported 
TB symptoms (Table 1).
Adults with TB-related death within 30 days after starting TB treatment were older than 
those who died more than 30 days after starting TB treatment (Table E2).
Death certificates were available for 1,093 of the 1,214 patients whose deaths could be 
classified as TB related or not using the study algorithm. We classified 847 deaths (77% of 
1,093) as TB related and 246 (23%) as TB unrelated. Of the 847 algorithm-defined TB-
related deaths, 469 (55%) had TB listed on the death certificate as the immediate, 
underlying, or contributing cause of death. Among adult patients with TB-related deaths, 
early death was more common if the death certificate did not mention TB. Almost two-thirds 
(66%) of those with no mention of TB on the death certificate died before treatment or 
within 30 days of treatment start, compared with 54% of those whose death certificates 
mentioned TB (P = 0.0001).
Compared with death determined to be related to TB by the study algorithm, the sensitivity 
of death certificate data (i.e., TB listed as underlying, immediate, or contributing cause of 
death) was 55% and specificity was 75%. Agreement between study algorithm and death 
certificate was modest (k = 0.21; 95% confidence interval [CI], 0.19–0.26) (Table E3).
In the case-control study, bivariable analysis showed that cases (adults with TB-related 
deaths who died during treatment) were more likely than control subjects (adults alive at 
least 2 years after treatment completion) to have severe or extensive disease: smear-positive 
disease (60% vs. 41%, P < 0.001), respiratory failure (50% vs. 3%, P < 0.001), bilateral 
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disease (47% vs. 26%, P < 0.001), extensive pulmonary destruction (36% vs. 21%, P < 
0.001), combined pulmonary and extrapulmonary disease (27% vs. 8%, P < 0.001), and 
meningeal disease (11% vs. 1%, P < 0.001).
Cases were also more likely to have been born in the United States (54% vs. 38%, P < 
0.001), to have had an initial diagnosis other than TB (43% vs. 27% P < 0.001), to have 
refused treatment at any time during the treatment course (6% vs. 3%, P = 0.001), to have 
cognitive impairment (28% vs. 5% P < 0.001), to have had drug interactions with other 
medications (3% vs. 1%, P = 0.02), to report any TB symptom (93% vs. 85%, P < 0.001), 
and to report weight loss (65% vs. 56%, P = 0.001), fever (55% vs. 44%, P < 0.001), 
shortness of breath (49% vs. 29%, P < 0.001), or loss of appetite (40% vs. 25%, P < 0.001) 
(Table 2). Cases were more likely to be HIV-positive (20% vs. 5%, P < 0.001) or to have 
unknown HIV status (40% vs. 23%, P < 0.001). Cases were less likely to report cough (64% 
vs. 75%, P < 0.001), night sweats (27% vs. 33%, P = 0.01), or hemoptysis (11% vs. 16%, P 
= 0.003). There was no difference between the two groups in the proportion of patients with 
diabetes mellitus (DM) (26% vs. 23%, P = 0.11).
Bivariate analyses also showed differences in receipt of health services. Cases were more 
likely to have been diagnosed as inpatients (89% vs. 54%, P < 0.001) and to have received a 
portion of the intensive phase of TB treatment as inpatients (79% vs. 25%, P < 0.001). Cases 
were less likely to have had a health department home visit, to have been interviewed within 
a week of the health department’s notification of their case, and to have had their home 
address recorded (11% vs. 1%, P < 0.001).
In multivariable analysis, factors associated with TB-related death while receiving TB 
treatment included receiving a portion of the intensive phase of therapy in the hospital 
(adjusted odds ratio [aOR], 6.5; 95% CI, 4.9–8.6), absence of pyrazinamide in the initial 
treatment regimen (aOR, 3.4; 95% CI, 1.9–6.0), cognitive impairment (aOR, 2.8; 95% CI, 
1.9–4.2), receiving immunosuppressive medications such as prednisone or tumor necrosis 
factor-α inhibitors (aOR, 2.5; 95% CI, 1.1–5.6), COPD (aOR, 2.4; 95% CI, 1.7–3.3), 
bilateral pulmonary disease (aOR, 2.2; 95% CI, 1.6–2.9), no sputa collection for smear 
microscopy during pulmonary TB evaluation (aOR, 2.2; 95% CI, 1.5–3.3), liver conditions 
(aOR, 1.9; 95% CI, 1.4–2.7), cancer (aOR, 1.9; 95% CI, 1.9–5.4), and receiving a diagnosis 
other than TB before the TB diagnosis (aOR, 1.6; 95% CI, 1.2–2.2) (Table 3). None of the 
interaction terms achieved statistical significance; therefore, they were not maintained in the 
final model.
Discussion
Tuberculosis, a treatable and preventable disease, contributed to death in almost three-
fourths of persons in our study who died with the disease in the United States. Persons who 
died from tuberculosis were less likely to have typical symptoms and signs of tuberculosis, 
yet, paradoxically, they had extensive disease. Clinicians must be aware of atypical 
presentations of tuberculosis, particularly in persons with extensive disease and in human 
immunodeficiency virus-infected persons, and have a low threshold for including 
tuberculosis in the differential diagnosis. For individuals without obvious risk factors for 
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tuberculosis, additional tools are needed to help clinicians focus sooner on the possibility of 
tuberculosis.
Almost three-fourths of persons with tuberculosis-related death died before diagnosis or 
within a month after treatment initiation. Many who died did not report tuberculosis 
symptoms, and few who died before treatment had cavities on chest radiograph, which may 
have obscured the diagnosis of tuberculosis, an infrequent disease in the United States. Our 
finding was consistent with other studies that found an association between atypical chest 
radiographic findings (i.e., noncavitary infiltrate) and death at diagnosis and before 
treatment (15, 16). In our study, persons with tuberculosis-related deaths were more likely to 
have had an initial nontuberculosis diagnosis, such as pneumonia. This finding suggests 
patients may die or experience increased risk of death while providers pursue other 
diagnoses.
In a systematic review evaluating risk factors for tuberculosis death during treatment, Waitt 
and Squire hypothesized that studies demonstrating an association between increased 
comorbidities, social isolation, and death from tuberculosis may be a caused by delays in 
presenting to a provider with symptoms (17). The role of cognitive impairment in death 
during tuberculosis treatment may be explained by patient delays in presenting to a provider 
(8, 17), but could also be independently associated with mortality.
When compared with those dying before diagnosis, cases who died during treatment were 
more likely to be human immunodeficiency virus-positive, to have pulmonary and 
extrapulmonary disease, and to have extensive pulmonary destruction and bilateral disease 
on chest radiograph. Human immunodeficiency virus infection was an independent risk 
factor for tuberculosis-related death in our study and others (15, 16, 18, 19). However, many 
decedents had unknown human immunodeficiency virus status, either because the test was 
not performed or the results were unknown. This finding underscores the importance of 
human immunodeficiency virus testing of all patients being evaluated for tuberculosis and 
extensive pulmonary and extrapulmonary conditions without a definitive diagnosis, because 
management of both tuberculosis and human immunodeficiency virus concurrently increases 
the likelihood of a successful outcome (20, 21).
Findings of significant abnormalities on chest radiograph or combined pulmonary/
extrapulmonary disease might increase the likelihood that the physician makes a 
tuberculosis diagnosis sooner. However, consistent with the extensive burden of disease, half 
the patients who died during treatment did so within a month of starting treatment.
Although previous studies identified diabetes mellitus as a risk factor for death in patients 
with tuberculosis (13, 22, 23), our study found that diabetes did not contribute to 
tuberculosis-related death. The literature has been inconsistent about the role of diabetes in 
tuberculosis treatment outcomes (24, 25).
Of note, 42 persons (6%) starting tuberculosis therapy had severe adverse reactions to 
antituberculosis medications, which may have exacerbated an underlying condition and led 
to death. In our study, the most common preexisting condition was liver disease. In a study 
evaluating mortality of patients with cirrhosis with and without tuberculosis, patients with 
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cirrhosis were found to have higher mortality 30 days to 1 year after starting treatment, 
suggesting that hepatotoxicity from tuberculosis treatment may be a source of higher 
mortality (26). Careful monitoring of patients with cirrhosis early in their treatment could 
prevent mortality.
Even after adjusting for age and factors that increased the risk of liver injury, we found that 
absence of pyrazinamide in the initial treatment regimen was associated with tuberculosis-
related death. Clinicians might not prescribe pyrazinamide to patients with risks for liver 
injury because of its potential hepatotoxicity (27). In fact, 24 of 59 (41%) patients who died 
during treatment without pyrazinamide had reported excess alcohol use or had viral hepatitis 
or cirrhosis, and only 3% had a pyrazinamide-resistant M. tuberculosis strain. Thus, the 
absence of pyrazinamide in the regimen may be partially explained by concerns about 
toxicity in patients with liver conditions, as drug resistance does not explain it. Further work 
is needed to understand the mechanism of pyrazinamide efficacy to develop drugs with a 
similar mechanism but without the toxicity.
As seen in previous studies, our study confirmed that death certificates might incompletely 
capture tuberculosis disease when it is related to death. As slightly more than half of patients 
with a death certificate and tuberculosis-related death had tuberculosis listed as an 
immediate, underlying, or contributing cause of death (55%), the sensitivity of the death 
certificate to find a tuberculosis-related death was modest (55%). One explanation for the 
lower detection of tuberculosis-related deaths by the death certificate is that tuberculosis 
might be diagnosed many weeks after death, when the culture becomes positive and the 
death certificate has already been completed.
Several features of tuberculosis-related death stand out in this study. Decedents often did not 
have the classic symptoms (cough, hemoptysis, cavities on chest radiograph), which made 
an illness that is uncommon in the United States even easier to miss. Human 
immunodeficiency virus infection and liver conditions complicate tuberculosis and are also 
potential markers for increased mortality risk. The risk factors identified in this study may 
form the basis for the development of a tuberculosis mortality risk score, analogous to those 
that have been used to predict mortality in patients with tuberculosis in the hospital (28) and 
intensive care unit (29, 30), which may help with earlier diagnosis, rapid treatment initiation, 
and enhanced care. A risk score for pulmonary tuberculosis using risk factors (similar to the 
ones we describe) that was developed using a derivation cohort and tested using a validation 
cohort was able to differentiate between low-, moderate-, and high-risk patients (31). 
Bilateral disease on chest radiograph; extensive pulmonary destruction; immunosuppression; 
meningeal, miliary, or peritoneal tuberculosis; cognitive impairment; and coexisting 
conditions of obstructive pulmonary disease, cancer, and underlying liver disease should be 
formally evaluated in scoring and predicting mortality. If scoring becomes routine, a high 
score could alert clinicians to patients who may benefit from more intensified management 
and monitoring. Even without a scoring system, when tuberculosis is diagnosed in a 
hospitalized patient, clinicians should recognize the increased risk of death.
Our study had limitations. We did not assess the impact of smoking on tuberculosis- related 
death and could not fully assess the impact of health department monitoring, because a large 
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proportion of patients died before there was an opportunity for such intervention. Because 
few hospital records noted the provision of directly observed therapy, its potential protective 
role could not be evaluated. Similarly, we could not evaluate the association between 
provider type and patient outcome, because patients who died were overwhelmingly cared 
for in the hospital, with multiple providers during at least some portion of their diagnosis 
and treatment. Our analysis also assumes that our algorithm for tuberculosis-related death 
was more accurate than the death certificate. Given that our classification was based on data 
from an extensive chart review of medical and public health records and multiple 
independent reviewers, we feel confident that any residual bias is smaller than what might 
have occurred had the study been conducted with death certificates only in the classification. 
Because the study design required extensive medical record review, we were unable to 
assess risk factors for tuberculosis-related death before presentation to a healthcare provider. 
Finally, these data were collected on cases reported in 2005 to 2006; because of the 
extensive nature of the study organization and chart review required, more recent data are 
not available.
Our study underscores the importance of preventing tuberculosis deaths by preventing 
tuberculosis disease in the first place. In low-incidence nations with current diagnostic tools, 
tuberculosis diagnosis is often missed or delayed, and tuberculosis deaths most often occur 
within weeks of diagnosis. Current tuberculosis treatment regimens are not always sufficient 
to reverse extensive disease. Finally, many patients who successfully complete 
antituberculosis treatment often live less robust and shorter lives (32–34).
Fortunately, the public health and medical community have tools (more specific tests in the 
form of interferon-g release assays and shorter treatment regimens that are more likely to be 
completed) to identify and treat latent tuberculosis infection (35–37). Increased testing and 
treatment for latent tuberculosis infection can reduce the number of persons who develop 
and die of this preventable disease.
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Figure 1. 
Tuberculosis (TB) relatedness and timing of deaths. *Five patients’ time-to-death could not 
be assessed due to missing dates. TB = tuberculosis.
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Figure 2. 
Kaplan-Meier curve comparing time to death for patients who died with tuberculosis (TB)-
related death to patients who died with TB-unrelated death. The lower line represents the 
probability of survival for patients with TB-related death. The upper line represents the 
probability of survival for patients with TB-unrelated death.
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Table 1.
Characteristics associated with death before or during tuberculosis treatment among 942 adults whose deaths 
were tuberculosis related
Characteristic Patients Who Died before
Treatment (n = 237)
Patients Who Died during
Treatment (n = 705)
P
value
Demographic
 Age, yr, mean, median (IQR) 65.8, 69.4 (50.7–81.5) 64.9, 66.1 (51.9–79.9)    0.3
Age group, yr    0.014
  18–44   45 (19) 100 (14)
  45–64   57 (24) 237 (34)
  65–85   96 (41) 284 (40)
  >85   39 (16) 84 (12)
 Male 157 (66) 481 (68)    0.6
 White non-Hispanic   95 (40) 290 (41)    0.8
 Black non-Hispanic   85 (36) 250 (35)    0.9
 Asian   54 (23) 153 (22)    0.7
 Hispanic   45 (19) 160 (23)    0.2
 U.S. born 124 (52) 378 (54)    0.7
Socioeconomic/behavioral*
 Unemployed 162 (68) 542 (77)    0.01
 Homeless 10(4) 64 (9)    0.02
 Incarcerated    5 (2) 17(2)    0.8
 Injection drug use    5 (2) 34 (5)    0.07
 Noninjection drug use   13(5) 75 (11)    0.02
 Excess alcohol   35 (15) 126 (18)    0.3
 Long-term care facility   29 (12) 110 (16)    0.2
Clinical
 Pulmonary TB only 165 (70) 440 (62)    0.5
 Extrapulmonary TB only   43 (18)   74 (11)    0.002
 Both pulmonary and extrapulmonary TB   29 (12) 191 (27)  <0.001
 Bilateral disease   91 (38) 328 (47)    0.03
 Cavities on chest image   24 (10) 180 (26)  <0.001
 Effusion   84 (35) 272 (39)    0.4
 Hemorrhage    7 (3)    7(1)   0.03
 Meningeal TB   23 (10)   75 (11)    0.7
 Gastrointestinal TB    1 (0.4)   28 (4)    0.01
 Peritoneal TB    7 (3)   26 (4)    0.6
 Miliary TB   20 (8)   48 (7)    0.4
 Pneumothorax    3(1)   25 (4)    0.07
 Extensive pulmonary destruction   44 (19) 252 (36)  <0.001
 Respiratory failure   97 (41) 352 (50)    0.02
 Smear positive†   88 (37) 423 (60)  <0.001
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Characteristic Patients Who Died before
Treatment (n = 237)
Patients Who Died during
Treatment (n = 705)
P
value
 Multidrug-resistant TB‡    1 (0.4) 13(2)    0.1
 History of TB    9 (4) 56 (8)    0.03
 HIV status  <0.001
  HIV negative   47 (20) 283 (40)
  HIV positive   29 (12) 141 (20)
  HIV test not offered   42 (18)   98 (14)
  HIV test refused    2(1)   24 (3)
  Unknown HIV test result 117 (49) 159 (23)
 Coronary artery disease   46 (19) 143 (20)    0.8
 Cancer   35 (15)   66 (9)    0.02
 COPD   55 (23) 184 (26)    0.4
 Condition affecting the liver§   59 (25) 215 (31)    0.1
 Cirrhosis   24 (10)   70 (10)    0.9
 Hepatitis (viral)   23 (10)   90 (13)    0.2
 Diabetes mellitus   52 (22) 183 (26)    0.2
 Cognitive impairment   61 (26) 198 (28)    0.5
 Physical inability to self-medicate   16 (7) 108 (15)  <0.001
 Immunosuppressive medications∥     5 (2)   40 (6)    0.03
 No reported TB symptom   50 (21)   48 (7)  <0.001
 Reported cough¶ 111 (59) 421 (64)    0.2
 Reported fever¶   83 (44) 358 (55)    0.01
 Reported hemoptysis¶   18 (10)   73 (11)    0.6
 Reported night sweats¶   26 (14) 178 (27)  <0.001
 Reported weight loss¶   81 (43) 424 (65)  <0.001
 Health care
  Early report** 227 (96) 695 (99)    0.01
  No insurance   25 (11)   75 (11)    0.9
  Competing diagnosis††   94 (40) 304 (43)    0.3
  NAAT not done 132 (56) 337 (48)    0.04
  TST not done 185 (78) 341 (48)  <0.001
  Incomplete evaluation‡‡ 120 (51) 126 (18)  <0.001
Definition of abbreviations: AFB = acid-fast bacilli; COPD = chronic obstructive pulmonary disease; HIV = human immunodeficiency virus; IQR 
= interquartile range; NAAT = nucleic acid amplification test; TB = tuberculosis; TST = tuberculin skin test.
Data presented as n (%) unless otherwise noted.
*Unemployed included all persons not seeking employment at the time of TB diagnosis; homeless included those without a stable home within 1 
year up to TB diagnosis; incarcerated included those who were incarcerated within 1 year up to TB diagnosis; injection drug use, noninjection drug 
use, excess alcohol use: each involved substances used within 1 year up to TB diagnosis; long-term care facility included those who lived in a long-
term care facility within 1 year up to TB diagnosis.
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†Smear-positive indicates positive on AFB smear microscopy. Comparison group was negative or unknown results on AFB smear microscopy.
‡
Multidrug-resistant group was a subgroup of culture-confirmed cases (n = 920) with known drug susceptibility test results (n = 755).
§
Patient had cirrhosis or viral hepatitis or reported using excess alcohol.
∥
Includes prednisone and tumor necrosis factor-α inhibitors.
¶
Denominators are for patients who reported any TB symptom—patients who died: before treatment = 187; during treatment = 657.
**
Report case to state TB control program within 10 days of diagnosis.
††A diagnosis other than TB was made before TB diagnosis.
‡‡
Patient pulmonary evaluation did not include collection of three consecutive sputumsamples forAFBsmearmicroscopy within 4 days of 
hospitalization, orwithin 30 days if the patient with pulmonary disease was diagnosed as an outpatient. For patients with extrapulmonary TB only, 
no imaging or laboratory tests were documented.
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Table 2.
Comparison of adult patients with tuberculosis-related deaths who died during treatment and control patients 
who completed treatment
Characteristic Patients Who Died during
Treatment (N = 705)
Control
Subjects (N = 1,039)
P
Value
Demographic
 Age, yr, mean, median (IQR) 64.9, 66.1 (51.9–79.9) 62.5, 66.9 (50.6–76.4) 0.01
 Male 481 (68) 666 (64) 0.08
 White non-Hispanic 290 (41) 413 (40)   0.6
 Black non-Hispanic 250 (35) 249 (24) <0.001
 Asian 153 (22) 370 (36) <0.001
 Hispanic 160 (23) 206 (20)   0.2
 U.S. born 378 (54) 399 (38) <0.001
Socioeconomic/behavioral
 Unemployed 542 (77) 633 (61) <0.001
 Homeless 64 (9) 56 (5) 0.003
 Incarcerated 17(2) 33 (3)   0.3
 Injection drug use 34 (5) 20 (2) <0.001
 Noninjection drug use 75 (11) 60 (6) <0.001
 Excess alcohol 126 (18) 110 (11) <0.001
 Long-term care facility 110 (16) 43 (4) <0.001
Clinical
 Pulmonary TB only 440 (62) 801 (77) <0.001
 Extrapulmonary TB only 74 (11) 156 (15) 0.006
 Both extrapulmonary and pulmonary TB 191 (27) 82 (8) <0.001
 Bilateral disease 328 (47) 269 (26) <0.001
 Cavities on chest image 180 (26) 254 (24)   0.6
 Effusion 272 (39) 183 (18) <0.001
 Hemorrhage 7(1) 4 (0.4)   0.1
 Meningeal TB 75 (11) 10(1) <0.001
 Gastrointestinal TB 28 (4) 14(1) <0.001
 Peritoneal TB 26 (4) 16 (1.5)  0.004
 Miliary TB 48 (7) 4 (0.4) <0.001
 Pneumothorax 25 (4) 2 (0.2) <0.001
 Extensive pulmonary destruction 252 (36) 216 (21) <0.001
 Respiratory failure 352 (50) 27 (3) <0.001
 Smear positive* 423 (60) 423 (41) <0.001
 Multidrug-resistant TB 13(2) 0 <0.001
 History of TB 56 (8) 71 (7)   0.4
 HIV status <0.001
  HIV negative 283 (40) 758 (73)
  HIV positive 141 (20) 47 (5)
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Characteristic Patients Who Died during
Treatment (N = 705)
Control
Subjects (N = 1,039)
P
Value
  HIV test not offered 98 (14) 57 (5)
  HIV test refused 24 (3) 57 (5)
  Unknown HIV test result 159 (23) 120 (12)
 Coronary artery disease 143 (20) 109 (10) <0.001
 Cancer 66 (9) 44 (4) <0.001
 COPD 184 (26) 130 (13) <0.001
 Condition affecting the liver† 215 (31) 166 (16) <0.001
 Cirrhosis 70 (10) 20 (2) <0.001
 Hepatitis (viral) 90 (13) 65 (6) <0.001
 Diabetes mellitus 183 (26) 235 (23)   0.1
 Renal failure 24 (3) 6 (0.6) <0.001
 Immunosuppressive medications‡ 40 (6) 18(2) <0.001
 Cognitive impairment 198 (28) 53 (5) <0.001
 Physical inability to self-medicate 108 (15) 27 (3) <0.001
 No reported TB symptom 48 (7) 161 (15) <0.001
 Reported cough§ 421 (64) 653 (75) <0.001
 Reported fever§ 358 (55) 383 (44) <0.001
 Reported weight loss§ 424 (65) 491 (56) <0.001
 Reported night sweats§ 178 (27) 289 (33) 0.01
 Reported shortness of breath§ 348 (49) 304 (29) <0.001
 Reported loss of appetite§ 285 (40) 256 (25) <0.001
 Reported chest pain§ 128 (18) 173 (17)   0.4
 Reported hemoptysis§ 73 (11) 144 (16) 0.003
 Health care
  Competing diagnosis∥ 304 (43) 280 (27) <0.001
  TST not done 341 (48) 332 (32) <0.001
  Incomplete evaluation¶ 126 (18) 110 (11) <0.001
 Treatment characteristics
  Initiated on RIPE 610 (87) 933 (90) 0.04
  PZA was excluded from initial treatment regimen 59 (8) 37 (4) <0.001
  DOT was initiated 232 (33) 874 (84)
<0.001**
  DOT missing data 414 (59) 46 (4)
  Treatment interruptions 92 (13) 210 (20) <0.001
  SAE from TB meds** 76 (11) 102 (10)   0.5
  TB treatment discontinued due to SAE of TB meds 64 (9) 73 (7)   0.1
  Drug interactions†† 19(3) 12(1) 0.02
  Patient refused treatment at any time during treatment course 42 (6) 29 (3) 0.001
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Characteristic Patients Who Died during
Treatment (N = 705)
Control
Subjects (N = 1,039)
P
Value
Health department activities‡‡
  Lost to follow-up ≥30 d 10 (1.4) 14 (1.3)   0.9
Definition of abbreviations: AFB = acid-fast bacilli; COPD = chronic obstructive pulmonary disease; DOT = directly observed therapy; HIV = 
human immunodeficiency virus; IQR = interquartile range; PZA = pyrazinamide; RIPE = rifampin, isoniazid, pyrazinamide and ethambutol; SAE = 
severe adverse events; TB = tuberculosis; TST = tuberculin skin test.
Data presented as n (%) unless otherwise noted.
*Smear-positive indicates positive on AFB smear microscopy. Comparison group was negative or unknown results on AFB smear microscopy.
†
Patient had cirrhosis or viral hepatitis or reported using excess alcohol.
‡
Includes prednisone, tumor necrosis factor-α inhibitors.
§
Denominators are for patients who reported any TB symptom—patients who died during treatment = 657; control patients who completed 
treatment = 878.
∥A diagnosis other than TB was made before TB diagnosis.
¶
Patient pulmonary evaluation did not include collection of three consecutive sputum samples for AFB smear microscopy within 4 days of 
hospitalization, or within 30 days if the patient with pulmonary disease was diagnosed as an outpatient. For patients with extrapulmonary TB only, 
no imaging or laboratory tests were documented.
**SAEs documented to be possible due to TB treatment include hepatitis, hepatic failure, seizures, anaphylaxis, thrombocytopenia, severe 
dermatitis, cardiac event.
††
Drug interactions between TB medications and other medications that patient was taking were documented.
‡‡Of patients who died during treatment, 339 (48%) died within 30 days. Patients who died within 30 days had limited opportunity to have a 
tracking interview or home visit within 30 days.
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Table 3.
Factors associated with tuberculosis-related death on treatment for tuberculosis: multivariate logistic 
regression comparing patients who died during TB treatment to control patients who completed treatment
 Factor Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
Age* 1.01 (1.002–1.01) 1.01 (1.003–1.02)
Sex (male vs. female)* 1.2 (1.0–1.5) 1.1 (0.8–1.5)
Meningeal TB* 12.3 (6.3–23.9) 13.2 (6.0–29.0)
HIV status*,†
HIV positive† 8.0 (5.6–11.5) 6.7 (4.1–10.8)
HIV test not offered† 4.6 (3.2–6.6) 4.3 (2.6–6.9)
HIV test refused† 1.1 (0.7–1.9) 1.4 (0.7–2.7)
HIV status unknown† 3.6 (2.7–4.7) 4.2 (2.9–6.1)
Miliary pattern on chest image 18.9 (6.8–52.7) 19.4 (5.4–69.8)
Initiated intensive phase of treatment as an 11.2 (8.9–14.0) 6.5 (4.9–8.6)
inpatient
Cognitive impairment 7.3 (5.3–10.0) 2.8 (1.9–4.2)
Diagnosed in long-term care facility 4.3 (3.0–6.2) 2.1 (1.3–3.4)
Immunosuppressive medications‡ 3.4 (1.9–6.0) 2.5 (1.1–5.6)
COPD 2.5 (1.9–3.2) 2.4 (1.7–3.3)
Pyrazinamide was excluded from initial 2.5 (1.6–3.8) 3.4 (1.9–6.0)
treatment regimen
Peritoneal TB 2.4 (1.3–4.6) 3.7 (1.6–8.4)
Cancer 2.3 (1.6–3.5) 3.2 (1.9–5.4)
Condition affecting the liver§ 2.3 (1.8–2.9) 1.9 (1.4–2.7)
Smear-positive∥ 2.2 (1.8–2.7) 2.5 (1.8–3.3)
Bilateral disease 2.2 (1.7–2.8) 2.2 (1.6–2.9)
Competing diagnosis¶ 2.1 (1.7–2.5) 1.6 (1.2–2.2)
Incomplete evaluation** 1.8 (1.4–2.4) 2.2 (1.5–3.3)
Definition of abbreviations: CI = confidence interval; COPD = chronic obstructive pulmonary disease; HIV = human immunodeficiency virus; OR 
= odds ratio; TB = tuberculosis.
*Covariates were included in the model a priori.
†
Reference category: patients with known negative HIV test results.
‡
Includes prednisone and tumor necrosis factor-α inhibitors.
§
Patient had cirrhosis or viral hepatitis or reported using excess alcohol.
∥Sputum sample demonstrated acid-fast bacilli with smear microscopy.
¶A diagnosis other than TB was made before TB diagnosis.
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**
Patient pulmonary evaluation did not include collection of three consecutive sputum samples for acidfast bacilli smear microscopy within 4 days 
of hospitalization, or within 30 days if the patient with pulmonary disease was diagnosed as an outpatient. For patients with extrapulmonary TB 
only, no imaging or laboratory tests were documented.
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